Free Trial
NASDAQ:ACRS

Aclaris Therapeutics Q2 2024 Earnings Report

Aclaris Therapeutics logo
$1.47 +0.02 (+1.52%)
As of 09:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aclaris Therapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Aclaris Therapeutics Revenue Results

Actual Revenue
$2.77 million
Expected Revenue
$1.74 million
Beat/Miss
Beat by +$1.03 million
YoY Revenue Growth
N/A

Aclaris Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Aclaris Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Tuesday, August 5, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aclaris Therapeutics Earnings Headlines

ACRS Aclaris Therapeutics, Inc. - Seeking Alpha
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Aclaris Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email.

About Aclaris Therapeutics

Aclaris Therapeutics (NASDAQ:ACRS) a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

View Aclaris Therapeutics Profile

More Earnings Resources from MarketBeat